(Q35120723)
Statements
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study (English)
Alfredo Berruti
Luigi Dogliotti
Mauro Papotti
Anna Ferrero
Maria Pia Brizzi
Elisabetta Nobili
Lucia Tozzi
Mirella Torta
Antonio D'Avolio
Adriano Massimiliano Priola
Nadia Birocco
1 reference